Skip to main content
TipRanks
Go Ultimate75% OFF

Microbot Medical (MBOT) AI Stock Analysis

1,234 Followers
MBOT

Microbot Medical

(NASDAQ:MBOT)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Microbot Medical (MBOT) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%MBOT-62.35%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$46.28M
Dividend Yield
―
Average Volume (3M)
880.00K
Price to Earnings (P/E)
-2.5
Beta (1Y)
1.30
Revenue Growth
―
EPS Growth
38.89%
Country
US
Employees
43
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Microbot Medical Business Overview & Revenue Model

Company Description

Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive p...

Microbot Medical Risk Analysis

Microbot Medical disclosed 46 risk factors in its most recent earnings report. Microbot Medical reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

2 New Risks
1.Our research and development program is dependent on the availability of certain components from suppliers, the delay in delivery of which could materially adversely affect our ongoing development and ability to manufacture and package devices in the timeframes currently expected.Q4, 2023
2.Existing and historical risks relating to our operations in Israel are being exacerbated by the current military actions and operations, and related activities, that commenced with the surprise attack on the State of Israel on October 7, 2023.Q4, 2023

Microbot Medical Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MBOT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
INFUINFU70Outperform$296.30M31.6115.77%―2.40%76.01%
KRMDKRMD57Neutral$151.38M-195.480.00%―18.43%78.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
MLSSMLSS44Neutral$25.10M-6.67-122.29%―3.93%48.18%
FEMYFEMY43Neutral$9.70M-0.36-114.48%―-4.21%78.58%

* Healthcare Sector Average

Performance Comparison

-50%0%50%MBOTINFUMLSSKRMDFEMYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MBOT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MBOTMicrobot Medical0.69-1.04-60.17%
INFUInfuSystem Holdings, Inc.14.795.5760.41%
MLSSMilestone Scientific Inc0.28-0.03-9.18%
KRMDRepro-Med Systems, Inc.3.49-0.91-20.68%
FEMYFemasys, Inc.1.12-14.89-93.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.